Canada Cannabis Exports: Medical Markets, Regulations & Trade Data

Executive Summary

Canada has emerged as the world's leading exporter of legal cannabis, shipping hundreds of millions of dollars worth of dried flower, oils, and extracts to international markets annually since federal legalization in 2018. Under the Cannabis Act (S.C. 2018, c. 16), Health Canada regulates a robust export framework that allows federally licensed producers to ship cannabis products to countries with compatible legal frameworks, primarily for medical use. Europe has become the dominant destination, with Germany, the United Kingdom, Poland, and Denmark importing significant volumes of Canadian cannabis to supply their medical programs. As of 2026, Canada's cannabis exports exceed $250 million annually, with licensed producers like Tilray Brands, Aurora Cannabis, and Canopy Growth maintaining dedicated international divisions. The export market represents a critical revenue stream for Canadian producers facing domestic oversupply and price compression, while positioning Canada as the global standard-bearer for regulated cannabis commerce. This international trade occurs within a complex regulatory environment involving Health Canada export permits, import permits from destination countries, and compliance with international treaties including the 1961 Single Convention on Narcotic Drugs.

Why This Matters

Canada's cannabis export industry affects thousands of jobs, billions in potential economic activity, and the medical treatment of patients across multiple continents. The sector employs approximately 8,000 Canadians directly in cultivation, processing, quality assurance, and logistics roles dedicated to international markets. For provinces like Ontario, British Columbia, and Quebec, cannabis exports represent a value-added agricultural export comparable to other controlled commodities. The international market provides essential demand absorption for Canadian licensed producers who built cultivation capacity anticipating higher domestic consumption than materialized. Without export revenue, multiple mid-tier producers would face insolvency. Export sales averaged 18-22% of total revenue for the top five Canadian cannabis companies in 2025, according to financial disclosures. For patients, Canadian exports ensure consistent supply of standardized medical cannabis in countries where domestic production remains insufficient or prohibited. German patients, for example, rely on Canadian imports for approximately 60% of their medical cannabis supply. The quality standards enforced by Health Canada—including Good Manufacturing Practices (GMP) certification—set global benchmarks that protect patient safety. The geopolitical dimension matters equally. Canada's first-mover advantage in creating a legal export framework positions the country as the template for international cannabis commerce as more nations liberalize. The export infrastructure built since 2018 creates network effects and institutional knowledge that competitors will struggle to replicate, even as countries like Israel, Colombia, and Australia develop their own export programs.

Background and History

Pre-Legalization Medical Exports (2013-2018)

Canada's cannabis export history began under the Marihuana for Medical Purposes Regulations (MMPR) in 2013, when Health Canada first permitted licensed producers to export dried cannabis for medical and scientific purposes. The initial framework was restrictive, requiring case-by-case ministerial approval and limiting exports to countries with established medical cannabis programs. Between 2013 and 2018, fewer than a dozen Canadian producers obtained export permits, shipping primarily to Israel, Chile, and Australia in small quantities for clinical research. The first significant commercial export occurred in 2016 when Tilray (then a private company) shipped cannabis to Croatia for a clinical trial. This established the precedent that Canadian cannabis could meet European Union GMP standards, a critical regulatory hurdle. By 2017, total Canadian cannabis exports reached approximately $12 million annually, representing less than 2% of the domestic medical market.

The Cannabis Act and Export Framework (2018)

The Cannabis Act, which received Royal Assent on June 21, 2018, established comprehensive export provisions under Part 9, Sections 62-68. The legislation authorized the Minister of Health to issue export permits to holders of federal cultivation, processing, or sale for medical purposes licenses. The Act required that destination countries have legal frameworks permitting cannabis importation and that exports comply with international treaty obligations. Health Canada published the Cannabis Regulations (SOR/2018-144) simultaneously, detailing the export permit application process. Applicants must provide import permits from destination countries, demonstrate GMP compliance, specify product types and quantities, and maintain chain-of-custody documentation. Export permits are valid for up to two years and can cover multiple shipments to the same destination. The regulatory framework distinguished between cannabis for medical/scientific purposes (permitted under international treaties) and adult-use cannabis (prohibited for export under Canada's treaty obligations). This distinction remains in effect as of 2026, limiting Canadian exports to medical markets despite domestic adult-use legalization.

European Market Development (2019-2021)

Germany's decision to rely on imports rather than domestic cultivation for its medical cannabis program created the foundation for Canada's European export boom. In 2019, Germany's Federal Institute for Drugs and Medical Devices (BfArM) issued import licenses to multiple Canadian producers after domestic cultivation tenders failed to meet demand projections. Canopy Growth, Aurora Cannabis, and Aphria (later Tilray) established German subsidiaries and secured multi-year supply contracts. The United Kingdom followed in 2019 after the Home Office rescheduled cannabis-based medicinal products following high-profile cases of pediatric epilepsy patients. British importers began sourcing from Canadian producers who could demonstrate pharmaceutical-grade quality control. Poland, Denmark, and the Netherlands expanded their medical programs simultaneously, all turning to Canadian suppliers. By 2020, European destinations accounted for 78% of Canadian cannabis exports by value. Total export value reached $127 million in 2020, a 450% increase from 2018. The COVID-19 pandemic briefly disrupted logistics but ultimately accelerated European demand as domestic cultivation projects faced construction delays.

Market Maturation and Competition (2022-2026)

The period from 2022 to 2026 saw Canadian export growth plateau as international competition intensified and European producers scaled operations. Israel, Portugal, and Colombia developed export-oriented cultivation sectors with lower production costs than Canada. Germany's domestic cultivation program, delayed multiple times, finally began production in 2024, reducing import dependence. Canadian producers responded by focusing on premium genetics, specialized extracts, and rare cannabinoid products where they maintained competitive advantages. Companies invested in EU-GMP certification for multiple facilities, established distribution partnerships, and pursued pharmaceutical-channel strategies rather than competing solely on price. As of 2026, Canada maintains approximately 45% market share of global legal cannabis exports, down from 72% in 2020 but still the largest single exporter. The export market has diversified beyond Europe, with Australia, Brazil, and Thailand emerging as significant destinations following their respective medical cannabis legalizations.

Key Players

Health Canada

Health Canada's Cannabis Licensing and Permits Division administers the export permit system and enforces compliance with the Cannabis Act. The agency processes approximately 800-1,000 export permit applications annually as of 2026. Health Canada conducts pre-export inspections, reviews GMP certifications, and coordinates with the Canada Border Services Agency (CBSA) on shipment documentation. The agency maintains bilateral agreements with regulatory counterparts in 23 countries to streamline permit processing and information sharing.

Tilray Brands

Tilray Brands operates the largest international cannabis distribution network among Canadian producers, with export revenue exceeding $95 million in fiscal 2025. Following its 2021 merger with Aphria, Tilray established subsidiaries in Germany, Portugal, and Australia. The company supplies medical cannabis to over 20,000 pharmacies across Europe and maintains EU-GMP certification at facilities in Ontario and British Columbia. Tilray's CC Pharma distribution subsidiary in Germany provides pharmaceutical-channel access that competitors lack.

Aurora Cannabis

Aurora Cannabis pioneered large-scale European exports through its Aurora Deutschland subsidiary and maintains supply agreements with major European distributors. The company exports from facilities in Alberta and Ontario, focusing on premium dried flower and full-spectrum oils. Aurora reported international revenue of $68 million in 2025, representing 31% of total company revenue. The company holds export permits for 18 countries and maintains strategic inventory in European Union warehouses to reduce delivery times.

Canopy Growth

Canopy Growth operates through its Spectrum Therapeutics international division, which generated $52 million in export revenue in 2025. The company maintains GMP-certified production at its Smiths Falls, Ontario campus and exports primarily to Germany, the United Kingdom, and Australia. Canopy's partnership with Constellation Brands provides capital for international market development that smaller competitors cannot match.

European Importers and Distributors

German pharmaceutical wholesalers including Sanacorp, Noweda, and PHOENIX Pharma serve as primary distribution channels for Canadian cannabis in Europe. These companies hold import licenses from BfArM and manage pharmacy distribution networks. In the United Kingdom, Grow Pharma and Lyphe Group import Canadian products for distribution through private clinics and the National Health Service. These distributors exert significant influence over pricing and product selection, often requiring exclusive supply arrangements.

Legal and Regulatory Framework

Domestic Canadian Law

The Cannabis Act (S.C. 2018, c. 16), Part 9, establishes the legal authority for cannabis exports and prohibits unauthorized international shipments. Section 62 permits export by federal license holders with ministerial authorization. Section 63 requires exporters to hold valid permits specifying destination, quantity, and product type. Section 64 prohibits export to countries without legal importation frameworks. Violations carry penalties up to 14 years imprisonment under Section 65. The Cannabis Regulations (SOR/2018-144), Division 8, detail permit application requirements. Applicants must submit import permits from destination countries (Section 152), provide product specifications including THC and CBD content (Section 153), and maintain records for seven years (Section 154). Export permits cost $1,641 CAD per application as of 2026.

International Treaty Obligations

Canada's cannabis exports operate within constraints imposed by the 1961 Single Convention on Narcotic Drugs and the 1971 Convention on Psychotropic Substances. Both treaties permit international trade in cannabis for medical and scientific purposes but prohibit trade for non-medical use. Canada's export framework limits shipments to medical-use destinations, even though domestic adult-use sales are legal. The International Narcotics Control Board (INCB) monitors Canadian exports through annual reporting requirements. Canada submits quarterly export data to the INCB, which verifies that destination countries have issued corresponding import authorizations. This system prevents diversion to illicit markets and maintains Canada's treaty compliance.

Destination Country Requirements

Each importing country maintains distinct regulatory requirements that Canadian exporters must satisfy. Germany requires BfArM import permits, EU-GMP certification, and German-language labeling. Products must meet specifications in the German Pharmacopoeia and undergo batch testing by German laboratories. The United Kingdom requires Home Office controlled drug import licenses, compliance with the Human Medicines Regulations 2012, and registration with the Medicines and Healthcare products Regulatory Agency (MHRA). Australia's Therapeutic Goods Administration (TGA) requires import permits under the Narcotic Drugs Act 1967 and compliance with the Therapeutic Goods Act 1989. Products must be manufactured in TGA-approved facilities and meet Australian quality standards. Poland requires permits from the Chief Pharmaceutical Inspector and compliance with European Medicines Agency guidelines.

Market and Business Implications

Revenue and Profitability

Export markets provide higher margins than domestic Canadian sales due to limited competition and pharmaceutical distribution channels. Canadian producers report average wholesale prices of $5.50-$7.00 CAD per gram for export products, compared to $3.00-$4.00 CAD per gram domestically. European retail prices range from €12-€18 per gram, with distributors and pharmacies capturing significant margins. However, export operations require substantial capital investment. EU-GMP certification costs $500,000-$2 million per facility and requires ongoing compliance audits. International logistics, insurance, and regulatory costs add $0.75-$1.25 CAD per gram to production costs. Only producers with annual export volumes exceeding 5,000 kilograms achieve profitability on international operations, according to industry analysts.

Production and Capacity Utilization

Export demand has enabled Canadian producers to utilize cultivation capacity that would otherwise remain idle due to domestic oversupply. As of 2026, Canada's licensed producers operate at approximately 42% of total cultivation capacity. Export orders account for capacity utilization of 8-12 percentage points, preventing facility closures and layoffs. Producers have optimized cultivation for export specifications, growing strains with specific cannabinoid profiles requested by international buyers. High-CBD strains like ACDC and Harlequin command premium export prices, as do rare cannabinoid products containing CBG, CBN, or THCV. Producers have also developed proprietary genetics for export markets, creating differentiation beyond commodity dried flower.

Competitive Dynamics

Canadian producers face intensifying competition from lower-cost producers in Colombia, Portugal, and Israel. Colombian producers benefit from year-round outdoor cultivation and labor costs 60-70% lower than Canada. Israeli producers leverage decades of research expertise and pharmaceutical industry integration. Portuguese producers offer EU-based production with lower logistics costs than transatlantic shipping. Canadian competitive advantages include regulatory credibility, established distribution relationships, genetic diversity, and quality consistency. Health Canada's rigorous licensing and inspection regime provides assurance to international buyers that competitors from less-regulated jurisdictions cannot match. Canadian producers have also invested in downstream processing capabilities—extraction, formulation, pharmaceutical packaging—that add value beyond raw cultivation.

Investment and Capital Flows

International expansion has attracted foreign investment into Canadian cannabis companies, with European pharmaceutical companies acquiring stakes in export-focused producers. German pharmaceutical distributor Dermapharm acquired Canopy Growth's German operations in 2023 for €90 million. British pharmaceutical company Jazz Pharmaceuticals maintains a strategic investment in Aurora Cannabis focused on international markets. However, the capital intensity of international expansion has strained smaller producers. Multiple mid-tier companies have exited export markets due to inability to fund GMP certification and international regulatory compliance. The export sector has consolidated around the top five producers, which account for 73% of total Canadian cannabis exports as of 2026.

What Experts Say

Industry analysts view Canadian cannabis exports as a mature market entering a competitive phase where differentiation and efficiency determine success. According to Prohibition Partners, a cannabis market research firm, Canadian export growth will average 3-5% annually through 2030, down from 25-30% annual growth in 2019-2021. The firm attributes slower growth to increased competition and European domestic production. Health Canada officials emphasize that the export framework prioritizes patient safety and treaty compliance over commercial expansion. In public statements, the agency has noted that export permit processing times average 45-60 days and that approximately 8% of applications are denied due to incomplete documentation or destination country concerns. European medical cannabis patient advocacy groups have expressed appreciation for Canadian supply reliability while calling for greater price competition. Patients in Germany pay €12-€15 per gram for Canadian medical cannabis, compared to €8-€10 per gram for domestic German production where available. Patient advocates argue that import dependence maintains artificially high prices. Trade policy experts note that Canada's export framework could serve as a model for other commodities where international trade occurs under treaty restrictions. The permit system balances commercial interests with regulatory obligations, creating a replicable template for controlled substance commerce.

State-by-State Breakdown

Ontario

Ontario hosts the largest concentration of export-oriented cannabis producers, with 14 facilities holding active export permits as of 2026. The province's proximity to Toronto Pearson International Airport provides logistics advantages for European shipments. Major exporters including Tilray, Canopy Growth, and Organigram maintain GMP-certified facilities in Ontario. The province exported approximately $112 million worth of cannabis in 2025, representing 44% of national export value.

British Columbia

British Columbia's cannabis producers focus on premium genetics and craft cultivation for export markets, with eight licensed producers holding export permits. The province's cultivation expertise and genetic diversity attract European buyers seeking specialized strains. BC producers exported $47 million worth of cannabis in 2025, emphasizing high-THC strains and full-spectrum extracts. Vancouver International Airport serves as the primary export gateway.

Alberta

Alberta's lower operating costs and large-scale cultivation facilities support commodity export production, with Aurora Cannabis operating the province's largest export-focused facility. The province exported $38 million worth of cannabis in 2025. Alberta producers compete primarily on price and volume, targeting bulk orders from European distributors. Calgary International Airport handles the majority of Alberta's cannabis exports.

Quebec

Quebec hosts four export-licensed producers, including Hexo and SQDC suppliers, with total 2025 exports of $29 million. The province's pharmaceutical manufacturing expertise has enabled producers to develop medicinal formulations for European markets. Quebec producers focus on oil extracts and capsules rather than dried flower, targeting pharmaceutical distribution channels.

What's Next

The Canadian cannabis export sector faces critical developments in 2026-2027 that will determine long-term viability and market share. Germany's adult-use legalization framework, expected to include domestic cultivation provisions, could reduce Canadian import volumes by 20-30% according to industry projections. However, German implementation timelines remain uncertain, and medical imports will continue during any transition period. Australia's export program expansion represents a growth opportunity for Canadian producers. The Australian government announced in June 2026 that it would streamline export permits for Australian producers, creating a potential competitor. However, Australian production costs remain higher than Canada's, and Canadian producers maintain established distribution relationships in European markets that Australian entrants will need years to develop. The United Kingdom's post-Brexit regulatory divergence from European Union standards creates both opportunities and challenges. British regulators have signaled interest in developing UK-specific cannabis quality standards that could differ from EU-GMP requirements. Canadian producers may need to pursue dual certification to maintain access to both markets. Health Canada has announced plans to review the export permit process in late 2026, with potential streamlining for established exporters with compliance track records. The agency is considering multi-year blanket permits for producers with five or more years of export history and no compliance violations. This could reduce administrative costs for major exporters while maintaining oversight. Brazil, Thailand, and South Africa represent emerging export destinations where Canadian producers are establishing relationships. Brazil's medical cannabis program, launched in 2024, currently relies entirely on imports. Thailand's 2025 medical cannabis regulations permit imports for domestic distribution. South Africa's Constitutional Court ruling legalizing personal cultivation has created interest in medical program development that could require imports during initial phases. The pharmaceutical integration trend will likely accelerate, with Canadian producers pursuing drug identification numbers (DINs) and new drug submissions to position cannabis products as prescription pharmaceuticals rather than botanical medicines. This strategy targets higher-margin pharmaceutical distribution and potential insurance reimbursement, but requires clinical trial investments that only the largest producers can afford.

Further Reading

• Cannabis Act (S.C. 2018, c. 16) - Full text at https://laws-lois.justice.gc.ca/eng/acts/C-24.5/
• Cannabis Regulations (SOR/2018-144) - Full text at https://laws-lois.justice.gc.ca/eng/regulations/SOR-2018-144/
• Health Canada Cannabis Licensing Portal - https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis.html
• 1961 Single Convention on Narcotic Drugs - Full text at https://www.unodc.org/unodc/en/treaties/single-convention.html
• International Narcotics Control Board Annual Report - https://www.incb.org/incb/en/publications/annual-reports/annual-report.html
• Germany Federal Institute for Drugs and Medical Devices (BfArM) Cannabis Information - https://www.bfarm.de/EN/Federal-Opium-Agency/Cannabis-as-medicine/_node.html
• European Medicines Agency Good Manufacturing Practice Guidelines - https://www.ema.europa.eu/en/human-regulatory/research-development/compliance/good-manufacturing-practice
• Prohibition Partners Global Cannabis Report - https://prohibitionpartners.com/reports/
• Statistics Canada Cannabis Economic Account - https://www150.statcan.gc.ca/n1/daily-quotidien/cannabis-eng.htm
• Tilray Brands International Operations Disclosure - Annual financial filings at https://www.sec.gov/